#1 Clinical Trials Search in Europe

Panitumumab

This article explores the use of panitumumab, a monoclonal antibody drug, in various clinical trials for cancer treatment. Panitumumab targets the epidermal growth factor receptor (EGFR) and is being studied in colorectal cancer, head and neck cancer, and other types of tumors. The trials aim to evaluate panitumumab’s efficacy, safety, and potential benefits when used alone or in combination with other treatments like chemotherapy and radiation therapy.

Table of Contents

What is Panitumumab?

Panitumumab, also known by its brand name Vectibix[1], is a type of medication called a monoclonal antibody. Monoclonal antibodies are laboratory-made proteins that act like human antibodies in the immune system. They are designed to recognize and attach to specific proteins in the body[1].

How Does Panitumumab Work?

Panitumumab works by targeting a specific protein called epidermal growth factor receptor (EGFR) that is found on the surface of some cancer cells. EGFR helps cancer cells grow and divide. By attaching to EGFR, panitumumab blocks its function and helps prevent cancer cells from growing[1].

What Conditions Does Panitumumab Treat?

Panitumumab is primarily used to treat:

  • Metastatic Colorectal Cancer: This is cancer that has spread from the colon or rectum to other parts of the body. Panitumumab is used in patients whose cancer has a normal (wild-type) RAS gene[2][3].
  • Head and Neck Squamous Cell Carcinoma: This is a type of cancer that begins in the flat cells that line the inside of the mouth, nose, and throat[4].

How is Panitumumab Administered?

Panitumumab is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The usual dose is 6 mg/kg of body weight, given every two weeks[2][1]. The infusion usually takes about 60 to 90 minutes. Your doctor will determine the appropriate dose and schedule based on your specific condition and response to treatment.

Current Clinical Trials

Several clinical trials are currently studying panitumumab to improve its effectiveness and explore new uses:

  • Combining panitumumab with different chemotherapy regimens like FOLFOXIRI (a combination of multiple chemotherapy drugs) for metastatic colorectal cancer[2][3].
  • Using panitumumab in combination with targeted liver therapy (hepatic arterial infusion) for colorectal cancer that has spread to the liver[5].
  • Exploring intermittent dosing schedules to potentially reduce side effects while maintaining effectiveness[6].
  • Using a special form of panitumumab (Zr-89 labeled) as an imaging tool to detect cancer spread in head and neck cancer patients[4].

Potential Side Effects

Like all medications, panitumumab can cause side effects. Common side effects may include:

  • Skin reactions (rash, itching, dryness)
  • Diarrhea
  • Nausea
  • Fatigue
  • Fever

Your healthcare team will monitor you closely for any side effects and can help manage them if they occur. It’s important to report any new symptoms or changes in your health to your doctor[6].

Aspect Details
Drug Name Panitumumab (also known as Vectibix)
Drug Type Monoclonal antibody targeting EGFR
Main Cancer Types Studied Colorectal cancer, head and neck squamous cell carcinoma, small bowel cancer
Common Dosing 6-9 mg/kg intravenously every 2 weeks
Key Outcome Measures Response rate, progression-free survival, overall survival, safety profile
Combination Therapies Studied with chemotherapy (e.g., FOLFIRI) and radiation therapy
Patient Selection Often focuses on patients with wild-type KRAS/NRAS genes
Common Side Effects Skin disorders, electrolyte abnormalities, infusion reactions

FAQ

  • What is panitumumab and how does it work? Panitumumab is a monoclonal antibody drug that targets the epidermal growth factor receptor (EGFR) on cancer cells. It works by attaching to EGFR and blocking signals that help cancer cells grow, potentially slowing or stopping tumor growth.
  • What types of cancer is panitumumab being studied for? Panitumumab is being studied in clinical trials for various cancers, including colorectal cancer, head and neck squamous cell carcinoma, and small bowel or ampulla of Vater cancer. Most trials focus on its use in advanced or metastatic cancers.
  • How is panitumumab administered in clinical trials? In most trials, panitumumab is given as an intravenous infusion, typically every 2 weeks. The dose is often calculated based on the patient's body weight, with common doses being 6 mg/kg or 9 mg/kg.
  • What are some potential side effects of panitumumab? Common side effects observed in clinical trials include skin disorders, electrolyte abnormalities, and infusion reactions. Some trials also monitor for interstitial lung disease and cardiac disorders. The severity and frequency of side effects can vary between patients.
  • How do researchers determine if panitumumab is effective in clinical trials? Researchers assess panitumumab's effectiveness using various measures, including tumor response rates, progression-free survival, overall survival, and disease control rates. They also evaluate the drug's safety profile and quality of life impacts on patients.

Ongoing Clinical Trials on Panitumumab

  • Study on Oxaliplatin with Drug Combination for Patients with Advanced Peritoneal Metastasis from Colorectal Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Trifluridine/Tipiracil with Panitumumab or Bevacizumab for Patients with Metastatic Colorectal Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • A study of S-241656 and a drug combination in patients with certain types of cancer involving KRAS, BRAF, or other RAS/MAPK mutations

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Denmark France Italy Spain

  • Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Portugal Spain

  • Study Comparing Avelumab and Standard Chemotherapy for Patients with Metastatic Colorectal Cancer with Microsatellite Instability

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Sotorasib and Panitumumab with Other Drug Combinations for Patients with Metastatic Colorectal Cancer and KRAS p.G12C Mutation

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Greece Italy Spain

  • Study on the Effectiveness of FOLFOX and Panitumumab for Patients with Metastatic Colorectal Cancer Without RAS Mutation

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

  • Comparing drug combinations with panitumumab for patients with RAS and B-RAF wild-type metastatic colorectal cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on Holmium-166 TARE and Maintenance Therapy with Capecitabine, Bevacizumab, and Drug Combination for Patients with Unresectable Liver-Colorectal Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of FOLFOX6m, Bevacizumab, and Irinotecan for Patients with Colorectal Cancer and Liver Metastases

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Panitumumab is a monoclonal antibody designed to target specific cancer cells.
  • EGFR (Epidermal Growth Factor Receptor): A protein found on the surface of some cells that helps them grow and divide. Panitumumab targets and blocks EGFR to potentially slow or stop cancer growth.
  • Metastatic cancer: Cancer that has spread from its original location to other parts of the body.
  • KRAS gene: A gene that can have mutations in some cancers. The status of the KRAS gene (wild-type or mutated) may affect how well a patient responds to certain targeted therapies like panitumumab.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Response rate: The percentage of patients whose cancer shrinks or disappears after treatment.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.
  • RECIST criteria: Response Evaluation Criteria In Solid Tumors – a standard way to measure how well a cancer patient responds to treatment.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.

References

  1. https://clinicaltrials.gov/study/NCT00842257
  2. https://clinicaltrials.gov/study/NCT01358812
  3. https://clinicaltrials.gov/study/NCT03231722
  4. https://clinicaltrials.gov/study/NCT05423197
  5. https://clinicaltrials.gov/study/NCT03069950
  6. https://clinicaltrials.gov/study/NCT04425239